secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001193125-22-314755
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio closes sale of rare pediatric disease PRV to argenx for $102M
--------------------------------------------------------------------------

- Completed sale of Rare Pediatric Disease Priority Review Voucher to argenx BV for $102M cash.
- PRV awarded under FDA program for SKYSONA approval for cerebral adrenoleukodystrophy.
- Transaction closed on Dec 29, 2022 after HSR waiting period expiration.
- Terms consistent with previously disclosed Asset Purchase Agreement from Nov 29, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/0001193125-22-314755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/d413031d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-314755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer